Evidence map›Paper›PMID 42518393›Full record

ReviewACS omega2026

Advances in Ligand Development for Wacker-Type Oxidation.

Xianwen Zeng, Liping Chen, Wenxuan Wang, Jinquan Zhang, Ziyan Meng

Abstract readReview
In one paragraph

Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xianwen ZengGannan Medical University, Ganzhou 341000, Jiangxi province, China.
Liping ChenGanzhou People's Hospital, Ganzhou 341000, Jiangxi province, China.
Wenxuan WangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410008, China.
Jinquan ZhangGannan Medical University, Ganzhou 341000, Jiangxi province, China.ORCID https://orcid.org/0000-0002-3848-5491
Ziyan MengKey Laboratory of Green and Healthy Livestock and Poultry Breeding Technology of Jiangxi Education Institutes, Ganzhou polytechnic college, Ganzhou 341000, Jiangxi province, China.ORCID https://orcid.org/0009-0007-7951-9233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wacker-type oxidation is a cornerstone catalytic transformation for alkene-to-carbonyl conversion in organic synthesis, with immense industrial and academic impact over six decades. However, the classic Wacker-Tsuji system suffers from inherent limitations, including corrosive chloride reliance, poor regiocontrol, noble metal dependence, catalyst deactivation, and sustainability issues, which severely restrict its synthetic utility. Ligand engineering has emerged as the central strategy to revolutionize this field, yet no comprehensive review dedicated to ligand-controlled Wacker-type oxidation has been reported to date. Herein, we systematically dissect the fundamental regulatory mechanisms of ligands in Wacker-type oxidation, and provide a holistic overview of state-of-the-art advances in ligand-modulated palladium catalysis, including chloride/copper-free systems, switchable Markovnikov/anti-Markovnikov regioselectivity, and asymmetric catalysis. We further summarize ligand-enabled palladium-free oxidation based on earth-abundant metals (Fe, Co, Ru, Cu), which achieves unprecedented anti-Markovnikov selectivity inaccessible to traditional Pd catalysts. Finally, we critically outline the key unresolved challenges and future perspectives in this field, aiming to provide rational guidance for the development of next-generation efficient, selective, and sustainable Wacker-type oxidation systems.

Identifiers

PMID42518393
PMCPMC13382664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.